Recent Scientific Advances in Vaccines for Shigella
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 October 2024 | Viewed by 69
Special Issue Editors
Interests: shigella; salmonella; diarrhea; enteric disease; enteric vaccines; global health
Interests: vaccines; immunology; enterics; B cells; global health; correlates of protection
Interests: enteric; vaccines; immunology; antibodies; T cells; B cells
Interests: global health; enteric disease epidemiology; enteric vaccines; mucosal immunity; vaccine adjuvants; vaccine delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diarrheal disease is a major global health problem, especially for children in low- to middle-income countries. Shigella is the leading etiology of diarrhea-associated mortality in children under 5 years of age and the second-leading etiology of diarrhea-associated mortality across all age groups. Shigella is also an important cause of Traveler’s diarrhea and has been associated with several post-infectious sequelae such as reactive arthritis and irritable bowel syndrome (IBS).
Antibiotic treatment is commonly prescribed for shigellosis, but the global spread of antimicrobial-resistant (AMR) Shigella strains threatens this treatment option. Accordingly, the World Health Organization (WHO) has designated Shigella spp. as Priority Pathogens for the development of new therapeutics or preventive measures. The development of an effective vaccine against Shigella represents the ideal solution to the intertwined global health issues of shigellosis and the rise in AMR Shigella.
A variety of Shigella vaccine candidates are in clinical testing, including conjugate vaccines, outer membrane vesicles, recombinant subunit vaccines, and live attenuated vaccines. In addition, the preclinical pipeline contains several more vaccine candidates, including killed whole-cell vaccines and multi-pathogen (combination) vaccines. This Special Issue will feature the latest advances in the Shigella vaccine field. We invite contributions regarding preclinical vaccine development and clinical findings, as well as assay development for the evaluation of vaccine immunogenicity and potential correlates of protection.
Dr. Akamol E. Suvarnapunya
Dr. Kristen A Clarkson
Dr. Renee M. Laird
Dr. August Louis Bourgeois
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Shigella
- vaccines
- global health
